Q-omics provides the consensus-scored CERS1 profile across patient tissues and cancer cell-line models. CERS1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CERS1 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, CERS1 RNA expression shows 14,227 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, THCA, and THYM as cancer lineages where CERS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CERS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CERS1 survival associations across molecular data types. CERS1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CERS1 RNA expression–survival associations across cancer types. High CERS1 expression shows unfavorable associations in UVM, MESO, LGG, ACC, COAD and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CERS1 RNA expression.
This table summarizes CERS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CERS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CERS1 shows lower tumor expression in COAD and higher tumor expression in THCA, UCEC, KIRP, LIHC and LUSC. The THCA box plot shows higher CERS1 RNA expression in tumor versus normal tissue (log2 FC = +0.697, t-test p < 0.001).
This table shows molecular features associated with CERS1 in patient tissues and cancer cell lines. In patient samples, CERS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CERS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
